Atrys Health S A : 2021 Results Preview presentation (non audited).

Results Preview

2021 Financial Year

10 March 2022

Disclaimer and Cautionary Statements

This document and the conference-call webcast (including the Q&A session) may contain forward looking statements and information (hereinafter, the "Statements") relating to ATRYS HEALTH .S.A., or ATRYS Group, (hereinafter indistinctly, "ATRYS", the "Company" or the "Group") or otherwise. These Statements may include financial forecasts and estimates based on assumptions or statements regarding plans, objectives and expectations that make reference to different matters, such as the customer base and its evolutions, growth of the different business lines and of the global business, market share, possible acquisitions, divestitures or other transactions, Company's results and other aspects related to the activity and situations of the Company.

The future statements or forecasts contained in this document can be identified, in certain cases, through the use of words such as "expectations", "anticipation", "purpose", "belief" or similar expressions, or their corresponding negative form, or by the nature of the predictions relating to strategies or plans or intentions. These Statements reflect the current views of ATRYS with respect of future events, do no represent, by their own nature, any guarantee of the future fulfilment, and are subject to risks and uncertainties that could cause the final developments and results to materially differ from those expressed or implied by such Statements. These risks and uncertainties include those identified in the documents containing more comprehensive information filed by ATRYS before the different supervisory authorities of the securities markets in which its shares are listed and, in particular, the Mercado Alternativo Bursátil (MaB).

Except as required by applicable law, ATRYS does not assume any obligation to publicly update the Statements to adapt them to events or circumstances taking place after the date hereof, including changes in the Company's business or business development strategy or any other unexpected circumstance. This document and the conference-call (including the Q&A session) may contain summarized, non-audited or non-GAAP financial information. The information contained herein and therein should therefore be considered as a whole and in conjunction with all the public information regarding the Company available, including any other documents released by the Company that may contain more detailed information.

Lastly, neither this document nor any of its contents constitutes an offer to purchase, sell or exchange, or a solicitation of any offer to purchase, sell or exchange any security, or recommendation or advice regarding any security.

This document and the conference-call webcast (including the Q&A session) may contain forward looking statements and information (hereinafter, the "Statements") relating to ATRYS HEALTH .S.A., or ATRYS Group, (hereinafter indistinctly, "ATRYS", the "Company" or the "Group") or otherwise. These Statements may include financial forecasts and estimates based on assumptions or statements regarding plans, objectives and expectations that make reference to different matters, such as the customer base and its evolutions, growth of the different business lines and of the global business, market share, possible acquisitions, divestitures or other transactions, Company's results and other aspects related to the activity and situations of the Company.

The Statements can be identified, in certain cases, through the use of words such as "forecast", "expectations", "anticipation", "aspiration", "purpose", "estimates", "Plan" or similar expressions or variations of such expressions. These Statements reflect the current views of ATRYS with respect of future events, do no represent, by their own nature, any guarantee of the future fulfilment, and are subject to risks and uncertainties that could cause the final developments and results to materially differ from those expressed or implied by such Statements. These risks and uncertainties include those identified in the documents containing more comprehensive information filed by ATRYS before the different supervisory authorities of the securities markets in which its shares are listed and, in particular, the Mercado Alternativo Bursátil (MaB).

Except as required by applicable law, ATRYS does not assume any obligation to publicly update the Statements to adapt them to events or circumstances taking place after the date hereof, including changes in the Company's business or business development strategy or any other unexpected circumstance.

This document and the conference-call (including the Q&A session) may contain summarized, non-audited or non-GAAP financial information. The information contained herein and therein should therefore be considered as a whole and in conjunction with all the public information regarding the Company available, including any other documents released by the Company that may contain more detailed information.

Neither this document nor the conference-call (including the Q&A session) nor any of their contents constitute an offer to purchase, sale or exchange any security, a solicitation of any offer to purchase, sale or exchange of any security, or recommendation or advice regarding any security.

01 - Atrys Equity Story.
04
02 - 2021 highlights.
08
03 - M&A strategy.
12
04 - 2021 performance.
16
05 - 2022 guidance.
24
06 - Annexes.	28

We are a global medical service provider with more than 2,200 professionals and 5,000 clients spread over 7 countries.

We are ATRYS

Our goal is to provide medical services thatmaximise efficiency in the diagnosis and treatment of patients through the application of innovative technology.

We have a solid organic and non-organicgrowth track record with the integration of 13 companies since 2018.

Listed on BME Growth since July 2016 andon the Continuous Market since February 2022 (ATRY.MC).

Group Performance

Leaders in B2B telemedicine (Radiology and Cardiology) in Spanish with operations in Spain, Chile, Colombia, Peru and Brazil.

Pioneers in high-precision radiation oncology in Europe with centres in Spain, Portugal and Switzerland.

Thirdcompanybymarketshare

occupational risk prevention in Spain.

in

First independent anatomical pathology and genetics laboratory in Spain.

CAGR = compound annual growth rate from 2016 to 2021.

Pro forma revenue performance 1:

We grow by combining organic growth (+17% CAGR 2016-2021) with the integration of companies with a strategic fit

Pro forma adjusted Ebitda (APM) performance 1:

Note 1: See the definition of Alternative Performance Measures (APM) in Annex I. Pro forma = Consolidates the companies acquired in each year to a full year.

5